Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.17 (
MMP-3
)
3,419
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Matrix metalloproteinases are secreted enzymes important in inflammation and tumor invasion. Earlier, we demonstrated that in normal human FS-4 fibroblasts, collagenase and
stromelysin
mRNA levels are increased not only after treatment with known matrix metalloproteinase inducers such as tumor necrosis factor (TNF), interleukin-1, and 12-O-tetradecanoylphorbol-13-acetate, but also with
interferon-beta
(
IFN-beta
). In this study, we compared the regulation of these matrix metalloproteinase genes by TNF and
IFN-beta
. We show that both TNF and
IFN-beta
increase steady-state levels of collagenase and
stromelysin
mRNAs with similar slow kinetics. The glucocorticoid dexamethasone blocked matrix metalloproteinase induction by both cytokines. The protein synthesis inhibitor cycloheximide inhibited collagenase mRNA induction by TNF or
IFN-beta
, suggesting that induction by both agents is indirect. Consistent with these observations, both TNF and
IFN-beta
increased c-fos and c-jun mRNA levels. Furthermore, treatment with TNF or
IFN-beta
increased the transcriptional activity of activator protein-1-responsive chloramphenicol acetyltransferase reporter gene constructs, including a native collagenase promoter-driven chloramphenicol acetyltransferase construct. These findings show that regulation of matrix metalloproteinase gene expression by both TNF and
IFN-beta
involves the transcription factor activator protein-1 and demonstrate a novel indirect mechanism of type I IFN-induced gene expression.
...
PMID:Interferon-beta induces metalloproteinase mRNA expression in human fibroblasts. Role of activator protein-1. 806 4
Interferon-beta
(
IFN-beta
) has a beneficial influence on the course of multiple sclerosis (MS) and has become standard treatment of this disease, though its mechanisms of action are incompletely understood. This study examines the effect of
IFN-beta
treatment on the cytokines IL-6, TNF-alpha, IFN-gamma and IL-10; the metalloproteinases
MMP-3
, -7 and -9 and the tissue inhibitor of metalloproteinase-1 (TIMP-1).
IFN-beta
treatment resulted in decreased numbers of mononuclear cells (MNC) secreting IL-6 and TNF-alpha and expressing mRNA of
MMP-3
and MMP-9 compared to pretreatment levels. On the contrary, numbers of IL-10 secreting MNC and TIMP-1 mRNA expressing were augmented during
IFN-beta
therapy. Whether the down-regulatory effects on pro-inflammatory and upregulatory effects on anti-inflammatory molecules are a direct result of
IFN-beta
on the immune system or secondary to clinical stabilization of MS pathology induced by
IFN-beta
remains to be evaluated.
...
PMID:Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. 1090 Mar 59